RyboDyn Revenue and Competitors
Estimated Revenue & Valuation
- RyboDyn's estimated annual revenue is currently $1.7M per year.
- RyboDyn's estimated revenue per employee is $155,000
Employee Data
- RyboDyn has 11 Employees.
- RyboDyn grew their employee count by 10% last year.
RyboDyn's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder and Chief Computational Officer | Reveal Email/Phone |
2 | Scientific Advisor | Reveal Email/Phone |
RyboDyn Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is RyboDyn?
RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our \targets-to-assets\ therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.
keywords:N/A
N/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 11 | N/A | N/A |
#2 | $1M | 11 | N/A | N/A |
#3 | $1M | 11 | N/A | N/A |
#4 | $1M | 11 | N/A | N/A |
#5 | $1M | 11 | N/A | N/A |